Cite
HARVARD Citation
Thieblemont, C. et al. (n.d.). POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO (AUGMENT). Hematological oncology. pp. 226-227. [Online].